Dalmia Bharat inching its way to become Pure-Play Cement Producer
M & A Critique|May 2023
Dalmia Bharat Limited ("DBL") has created a Vision 2031 for capacity creation plan of 110-130 million tons from existing capacity of 40 million tons of cement manufacturing.
Dalmia Bharat inching its way to become Pure-Play Cement Producer

In a move to fund its ambitious plan, DBL started to hive-off their non-core assets. In pursuant to the same, DBL announced divestment of its entire 42.36% equity interest in Dalmia Bharat Refractories Limited ("DBRL") held through it WoS Dalmia Cement [Bharat) Limited (DCBL).

Dalmia Bharat Limited ("DBL") is the fourth-largest cement manufacturing company in India by installed capacity. Spread across 10 states and 14 manufacturing units, DBL is a category leader in super-specialty cement used for oil well, railway sleepers and airstrips and is the country's largest producer of Portland Slag Cement (PSC). The equity shares of DBL are listed on nationwide bourses.

Dalmia Cement (Bharat) Limited, a wholly owned subsidiary of DBL inter-alia was holding 42.36% stake in Dalmia Bharat Refractories Limited ("DBRL").

Dalmia Bharat Refractories Limited ("DBRL") was engaged in providing a complete line of services including refractory design and layout for greenfield projects, refractory application and maintenance. In January 2023, DRBL sold its entire India Refractory Business to RHI Magnesita India Limited against 2,70,00,000 equity shares of RHI Magnesita India Limited representing circa 13.25% Stake valued at circa INR 1800 crore. The Equity shares of DBRL are listed on Metropolitan Stock Exchange & Calcutta Stock Exchange.

At the time of this transaction, DBRL shareholding pattern was 42.36% by DCL (through DCBL), 32.63% by Dalmia family in their personal capacity (total promoter holding being 74.99%) while remaining 25.01% is owned by public shareholders.

The Transaction

DCBL has entered into a binding agreement to sell its 42.36% stake in DBRL to a promoter group company called Sarvapriya Healthcare Solutions Private Limited at a consideration of ₹800 crores. The payment consideration for the same will come in as follows:

هذه القصة مأخوذة من طبعة May 2023 من M & A Critique.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 8500 مجلة وصحيفة.

هذه القصة مأخوذة من طبعة May 2023 من M & A Critique.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 8500 مجلة وصحيفة.

المزيد من القصص من M & A CRITIQUE مشاهدة الكل
Batliboi Ltd. merging its associate company
M & A Critique

Batliboi Ltd. merging its associate company

Batliboi Limited has a history of collaborations with various foreign technical partners and has subsidiaries like Hydraulic & General Engineers Ltd. and Batliboi International Ltd. In March 2024, the board of Directors of Batliboi Limited accorded their approval for the merger of promoter owned private company with itself.

time-read
2 mins  |
May 2024
TVS Motors issuances of convertible preference shares as bonus instead of dividend
M & A Critique

TVS Motors issuances of convertible preference shares as bonus instead of dividend

Recently, well known auto manufacturer announced the issuance of preference shares as a bonus to all equity shareholders.

time-read
3 mins  |
May 2024
Aditya Birla Fashion & Retails Scheme to undo its consolidation
M & A Critique

Aditya Birla Fashion & Retails Scheme to undo its consolidation

Corporate restructuring saga continues for Aditya Birla Group.

time-read
5 mins  |
May 2024
Advent International to combine its listed & private entity business
M & A Critique

Advent International to combine its listed & private entity business

Recently, Advent International announced the merger of its privately held pharma company into recently acquired listed pharma company.

time-read
6 mins  |
April 2024
Eris Lifesciences on Acquisition Spree to expand its branded formulations portfolio
M & A Critique

Eris Lifesciences on Acquisition Spree to expand its branded formulations portfolio

Recently, Eris Lifesciences Limited announced acquisition of 'branded Formulation Business' of Biocon Biologics Limited pertaining to the India territory through slump sale. In addition, ELL also announced a foreign acquisition.

time-read
7 mins  |
April 2024
Vuenow Merges All Entities Will It Create Value?
M & A Critique

Vuenow Merges All Entities Will It Create Value?

Recently, Vuenow Infratech Limited, a BSE listed company, announced the merger of two private companies itself.

time-read
6 mins  |
April 2024
Dalmia Group continues its journey of segregation of businesses by way of demerger
M & A Critique

Dalmia Group continues its journey of segregation of businesses by way of demerger

Recently Dalmia Group announced yet another restructuring of one of its group companies Dalmia Bharat Refractories Limited.

time-read
6 mins  |
March 2024
Rane Group to consolidate its listed operational entities
M & A Critique

Rane Group to consolidate its listed operational entities

After keeping different operational listed entities for years, Rane Group, one of the key players in Auto Ancillary space has decided to consolidate its listed operational companies under Rane (Madras) Limited.

time-read
3 mins  |
March 2024
Zuari Group's attempts to create the biggest private producer of Fertilisers
M & A Critique

Zuari Group's attempts to create the biggest private producer of Fertilisers

“Transfer of Identified shares from ZACL to ZMPPL is a precondition for approval of the merger transaction”

time-read
7 mins  |
March 2024
Shankara Building Products separates its trading & marketplace business for independent growth
M & A Critique

Shankara Building Products separates its trading & marketplace business for independent growth

Recently, Shankara Building Products Limited announced the demerger of its trading/building material marketplace business from its manufacturing business.

time-read
4 mins  |
February 2024